Keywords

• Artemisinin
• Artemisinin powder
• 99% Artemisinin

Quick Details

• ProName: cas 2349386-89-4 99 % Molnupiravir po...
• CasNo: 63968-64-9
• Molecular Formula: C15H22O5
• Appearance: white
• Application: Artemisia annua is used as antimalaria...
• DeliveryTime: 7-10 days
• PackAge: drum
• Port: Shanghai/Wuhan
• ProductionCapacity: 1000 Kilogram/Day
• Purity: 99
• Storage: room
• LimitNum: 1 Kilogram

Superiority

cas 2349386-89-4  99 % Molnupiravir powder 

Product Name:    Molnupiravir
CAS:    2349386-89-4
MF:    C13H19N3O7
MW:    329.31
EINECS:    604-604-1 

EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine . It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) 

EIDD 2801 is an orally bioavailable broad-spectrum antiviral that inhibits SARS-CoV-2 and other multiple endemic, epidemic and bat coronavirus and has the potential for seasonal and pandemic influenza treatment. An isopropylester prodrug of the ribonucleoside analog of EIDD-1931 that exhibits anti-influenza virus and coronaviruses activities.

Details

cas 2349386-89-4  99 % Molnupiravir powder 

Product Name:    Molnupiravir
CAS:    2349386-89-4
MF:    C13H19N3O7
MW:    329.31
EINECS:    604-604-1 

EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine . It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) 

EIDD 2801 is an orally bioavailable broad-spectrum antiviral that inhibits SARS-CoV-2 and other multiple endemic, epidemic and bat coronavirus and has the potential for seasonal and pandemic influenza treatment. An isopropylester prodrug of the ribonucleoside analog of EIDD-1931 that exhibits anti-influenza virus and coronaviruses activities.